P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer

Sasmit Sarangi, Ambarish Pandey, Anne Laure Papa, Poulomi Sengupta, Jawahar Kopparam, Ushashi Dadwal, Sudipta Basu, Shiladitya Sengupta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

Original languageEnglish (US)
Article number567
JournalMedical Oncology
Volume30
Issue number2
DOIs
StatePublished - Jun 1 2013

Fingerprint

Cisplatin
Breast Neoplasms
Cell Line
Up-Regulation
Carcinoma
Glioma
Neoplasms
Colon
Kidney

Keywords

  • Breast cancer
  • Cisplatin
  • HIF1α
  • P2Y12 receptor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sarangi, S., Pandey, A., Papa, A. L., Sengupta, P., Kopparam, J., Dadwal, U., ... Sengupta, S. (2013). P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Medical Oncology, 30(2), [567]. https://doi.org/10.1007/s12032-013-0567-y

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. / Sarangi, Sasmit; Pandey, Ambarish; Papa, Anne Laure; Sengupta, Poulomi; Kopparam, Jawahar; Dadwal, Ushashi; Basu, Sudipta; Sengupta, Shiladitya.

In: Medical Oncology, Vol. 30, No. 2, 567, 01.06.2013.

Research output: Contribution to journalArticle

Sarangi, S, Pandey, A, Papa, AL, Sengupta, P, Kopparam, J, Dadwal, U, Basu, S & Sengupta, S 2013, 'P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer', Medical Oncology, vol. 30, no. 2, 567. https://doi.org/10.1007/s12032-013-0567-y
Sarangi, Sasmit ; Pandey, Ambarish ; Papa, Anne Laure ; Sengupta, Poulomi ; Kopparam, Jawahar ; Dadwal, Ushashi ; Basu, Sudipta ; Sengupta, Shiladitya. / P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. In: Medical Oncology. 2013 ; Vol. 30, No. 2.
@article{92865261b47e48e8bfd500f8fc927a83,
title = "P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer",
abstract = "Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.",
keywords = "Breast cancer, Cisplatin, HIF1α, P2Y12 receptor",
author = "Sasmit Sarangi and Ambarish Pandey and Papa, {Anne Laure} and Poulomi Sengupta and Jawahar Kopparam and Ushashi Dadwal and Sudipta Basu and Shiladitya Sengupta",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s12032-013-0567-y",
language = "English (US)",
volume = "30",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer

AU - Sarangi, Sasmit

AU - Pandey, Ambarish

AU - Papa, Anne Laure

AU - Sengupta, Poulomi

AU - Kopparam, Jawahar

AU - Dadwal, Ushashi

AU - Basu, Sudipta

AU - Sengupta, Shiladitya

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

AB - Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

KW - Breast cancer

KW - Cisplatin

KW - HIF1α

KW - P2Y12 receptor

UR - http://www.scopus.com/inward/record.url?scp=84875822280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875822280&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0567-y

DO - 10.1007/s12032-013-0567-y

M3 - Article

C2 - 23568163

AN - SCOPUS:84875822280

VL - 30

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

M1 - 567

ER -